Providence Health & Services

- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1859-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.providence.org
Clinical Trials
81
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (70 trials with phase data)• Click on a phase to view related trials
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 110
- Registration Number
- NCT06719362
- Locations
- 🇺🇸
Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 12
- Registration Number
- NCT06353997
- Locations
- 🇺🇸
Ellison Institute of Technology (EITM), Los Angeles, California, United States
🇺🇸Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
🇺🇸Providence St. Vincent Medical Center, Portland, Oregon, United States
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 28
- Registration Number
- NCT06175000
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Providence Health & Services; Providence Neurological Specialties, Portland, Oregon, United States
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
- Conditions
- Metastatic MelanomaHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 92
- Registration Number
- NCT05913388
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
Clinical Outcomes and Patient Satisfaction With Use of the Amma System
- Conditions
- Breast Cancer
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 15
- Registration Number
- NCT05508984
- Locations
- 🇺🇸
Providence Cancer Institute - Newberg Clinic, Newberg, Oregon, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸Providence Oncology and Hematology Care - Westside, Portland, Oregon, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 17
- Next